Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
- Ebola is a lethal disease. A lot is still unknown about Ebola and its long-term effects. Researchers want to learn what ill health conditions Ebola survivors have. They want to learn if Ebola survivors can infect others in their household through close contact. They also want to learn if Ebola survivors are immune from getting Ebola again. To learn these things, they want to follow people in Liberia for 5 years.
- To learn how Ebola affects the health of survivors and the people they live with.
- People in Liberia who had Ebola in the past 2 years, who share a household with someone who had Ebola, or who got ill and went to an Ebola Treatment Unit but were sent home because they did not have Ebola.
- Participants will be screened with family illness history, physical exam, and blood tests. They may have an eye exam.
- Ebola survivors and those who went to a Treatment Unit but did not have Ebola will visit a clinic at 3, 6, and 12 months, then every 6 months for 5 years. At each visit, they will repeat the screening tests.
- Participants who live with someone who had Ebola will have only the screening visit. But they may be asked to return for follow-up visits. These visits will help researchers learn more about the differences between those who have had Ebola and those who have not.
- Participants brought to the NIH Clinical Center will have documentation of positive Ebola virus PCR and a clinical syndrome compatible with acute EVD.
- The study will last 5 years.
Ebola Virus Disease
|Study Design:||Time Perspective: Prospective|
|Official Title:||Partnership for Research on Ebola Virus (PREVAIL) III: Ebola Natural History Study|
- To characterize the clinical sequelae seen in convalescent Ebola virus disease (EVD) patients. [ Time Frame: 10 years ]
- Assess whether convalescent EVD patients can transmit infection to household and sexual contacts as determined by development of EVD or Ebola seroconversion in contacts [ Time Frame: 10 years ]
- Better define the immune response in EVD survivors. [ Time Frame: 10 years ]
|Study Start Date:||April 24, 2015|
|Estimated Study Completion Date:||January 1, 2030|
|Estimated Primary Completion Date:||May 31, 2025 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT02431923
|Contact: Michael C Sneller, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 email@example.com|
|Monrovia Medical Unit ELWA-2 Hospital||Recruiting|
|Principal Investigator:||Michael C Sneller, M.D.||National Institute of Allergy and Infectious Diseases (NIAID)|